



QUINOLINE VETERANS AND FAMILIES ASSOCIATION

SUPPLEMENTARY SUBMISSION TO THE FOREIGN AFFAIRS, DEFENCE AND TRADE REFERENCES COMMITTEE INQUIRY INTO THE USE OF THE QUINOLINE ANTI-MALARIAL DRUGS MEFLOQUINE AND TAFENOQUINE IN THE AUSTRALIAN DEFENCE FORCE

Mr Stuart McCarthy, 13 September 2018

QVFA thanks the Committee for their continued efforts with this inquiry. The purpose of this supplementary submission is to draw the Committee's attention to additional evidence regarding the false and misleading testimony provided by Mr Mark Reid at the Brisbane hearing on 30 August 2018. Mr Reid falsely testified that the U.S. military has not paid 60 Degrees Pharmaceuticals (60P) for the development of tafenoquine.

During the Brisbane hearing Senator O'Sullivan asked Mr Reid directly whether the U.S. military had paid 60P:

CHAIR: *So, because there's not a great market in the poor nations of the world and in the military for these drugs, there's no money in it for any pharmaceutical provider?*

Mr Reid : That's correct.

Senator O'SULLIVAN: I just want to try and get these relationship lines, because they're important, as you'd appreciate, as we give weight to the various testimonies that are provided. Is it the case that the US military, using public funding, socialised funding, paid 60 Degrees to embark on this journey?

Mr Reid : No. They're not allowed to.

Senator O'SULLIVAN: Did they have a partnership with 60 Degrees?

Mr Reid : It's a data-sharing agreement.

The 60P "investors" webpage (attached) states that the U.S. Army has provided 60P with \$US18+ million in funding, in addition to licensing agreements, sponsorship rights and patents for tafenoquine:


Secured research and licensing agreements, sponsorship rights, and use patents with the U.S. Army.

Ongoing U.S. Army support - \$US18+ million for development program.

Mr Reid's testimony to the effect that the U.S. military has not provided public funding to 60P for the development of tafenoquine was false. I trust that this will assist the Committee with its ongoing inquiry.

Attachments

1. 60 Degrees Pharmaceuticals, "Investors" webpage, accessed 12 September 2018.
<https://60degreespharma.com/investors/>



INVESTORS: CAPTURE NEW, UNADDRESSED MARKET OPPORTUNITIES

60° PHARMACEUTICALS (60P): A TWO-PRONGED MISSION FOR INVESTORS

- Commitment to developing new therapies for the treatment and prevention of tropical diseases
- Privately held company that is interested in a healthy return on investment

INVESTING IN AN ESTABLISHED MARKET

A tremendous investment opportunity exists due to the ineffective preventative malaria therapies currently on the market along with expanding disease risks. This calls for more effective and efficient prevention therapies.

60P: EXCLUSIVE RIGHTS TO DEVELOP TAFENOQUINE (FOR MALARIA PREVENTION)

- Secured research and licensing agreements, sponsorships rights, and use patents with the U.S. Army
- Ongoing U.S. Army-support \$US18+ million for development program

COMPETITIVE ADVANTAGES IN DENGUE FEVER TREATMENT

- **Celgosivir and Modipafant: Decreasing disease burden**
 - Targeted usage will be to prevent or reduce the incidence and duration of illness and/or disease severity
 - Fills treatment void: Currently no effective therapeutic products against dengue
 - **60P: Significant clinical development achievements**
-